Drugs / 67Cu-SAR-BBN
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT05633160 | Jun 2023 → Apr 2025 | prostate carcinoma | Clarity Pharmaceuticals Ltd | Terminated | No outcome recorded Stop: Business |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 67Cu-SAR-BBN | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05633160 ↗ |